Genscript Biotech Corporation (GNNSF) Stock Analysis

Genscript Biotech Corporation (GNNSF) Healthcare & Pipeline Overview

Genscript Biotech Corporation is a global biotechnology company focused on life science research products and services, biologics development, industrial synthetic biology, and cell therapy. With a presence in North America, Europe, Asia Pacific, and China, Genscript serves diverse sectors, including pharmaceuticals, diagnostics, and agriculture.

What Is the Investment Thesis for GNNSF?

Genscript Biotech Corporation presents a notable research candidate within the biotechnology sector, driven by its diverse service offerings and global reach. Key value drivers include the continued expansion of its biologics development services and the growth of its cell therapy segment, particularly in the development of CAR-T therapies. The company's established presence in key markets like North America, Europe, and China provides a solid foundation for future growth. However, potential risks include regulatory hurdles, competition from established players, and the inherent uncertainties associated with drug development. Investors should monitor the progress of Genscript's clinical trials and its ability to maintain a competitive edge in the rapidly evolving biotechnology landscape.

Based on FMP financials and quantitative analysis

GNNSF Key Highlights

Genscript Biotech Corporation operates in four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy.

• The company was founded in 2002 and is headquartered in Nanjing, China.
• Genscript Biotech Corporation has a market capitalization of $8.96B as of 2026-03-17.
• The company employs 5568 individuals.
• Genscript Biotech Corporation serves customers in North America, Europe, the People's Republic of China, Japan, and other Asia Pacific regions.

Who Are GNNSF's Competitors?

GNNSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are GNNSF's Key Strengths?

Diverse service offerings across multiple segments of the biotechnology industry.

• Global presence and established customer base.
• Proprietary technologies and intellectual property.
• Strong reputation and brand recognition.

What Are GNNSF's Weaknesses?

Reliance on outsourced research and development spending.

• Exposure to regulatory risks and uncertainties.
• Competition from established players in the biotechnology industry.
• Dependence on key personnel and scientific expertise.

What Could Drive GNNSF Stock Higher?

Progress in clinical trials for cell therapy candidates.

• Expansion of biologics development services.
• Penetration of industrial synthetic biology products.
• Geographic expansion into new markets.
• Strategic partnerships and acquisitions.

What Are the Key Risks for GNNSF?

Negative return on equity (-16.2%) — the business is not currently generating profit on shareholder capital.

• Regulatory hurdles and delays in drug approvals.
• Competition from established players in the biotechnology industry.
• Economic downturn and reduced research and development spending.
• Technological obsolescence and disruption.
• Dependence on key personnel and scientific expertise.

What Are the Growth Opportunities for GNNSF?

• Expansion of Biologics Development Services: Genscript can capitalize on the increasing demand for biologics development services by expanding its capabilities in antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development. The global biologics market is projected to reach $457 billion by 2026, presenting a significant growth opportunity for Genscript. Timeline: Ongoing.
• Growth in Cell Therapy Segment: The cell therapy market, particularly CAR-T therapies, is experiencing rapid growth due to its potential in treating liquid and solid tumors. Genscript's focus on discovering and developing CAR-T therapies positions it to benefit from this trend. The global CAR-T therapy market is expected to reach $4.9 billion by 2027. Timeline: Ongoing.
• Penetration of Industrial Synthetic Biology Products: Genscript can expand its presence in the industrial synthetic biology market by developing and producing industrial enzymes for food processing, feed, pharmaceutical, and chemical industries. The global industrial enzymes market is projected to reach $7.0 billion by 2027, offering a substantial growth opportunity. Timeline: Ongoing.
• Geographic Expansion: Genscript can further expand its global presence by penetrating new geographic markets, particularly in emerging economies with growing healthcare sectors. This expansion can be achieved through strategic partnerships, acquisitions, or organic growth. Timeline: Ongoing.
• Strategic Partnerships and Acquisitions: Genscript can pursue strategic partnerships and acquisitions to expand its service offerings, access new technologies, and strengthen its market position. These partnerships can provide access to complementary expertise and resources, accelerating growth and innovation. Timeline: Ongoing.

What Threats Does GNNSF Face?

• Economic downturn and reduced research and development spending.
• Technological obsolescence and disruption.
• Increased competition and price pressure.
• Adverse regulatory changes and clinical trial failures.

What Are GNNSF's Competitive Advantages?

• Proprietary technologies and intellectual property in gene synthesis and protein engineering.
• Established reputation and brand recognition in the life science research market.
• Global presence and extensive customer base.
• Integrated service offerings across multiple segments of the biotechnology industry.

What Does GNNSF Do?

Founded in 2002 and headquartered in Nanjing, China, Genscript Biotech Corporation has evolved into a key player in the life science industry. The company operates through four distinct segments. The Life Science Services and Products segment offers a range of research services, including gene synthesis, molecular cloning, and antibody development, catering to basic biology studies, pharmaceutical discovery, and disease diagnostics. The Biologics Development Services segment provides antibody drug discovery, pre-clinical and clinical development, and gene and cell therapy development for pharmaceutical, biotech, government, and academic clients. The Industrial Synthetic Biology Products segment focuses on constructing non-pathogenic microbial strains and producing industrial enzymes for the food processing, feed, pharmaceutical, and chemical industries. The Cell Therapy segment is dedicated to discovering and developing chimeric antigen receptor T-cell therapies for treating liquid and solid tumors. Genscript's global presence spans North America, Europe, China, Japan, and other Asia Pacific regions, serving a diverse customer base across various industries.

What Products and Services Does GNNSF Offer?

• Provides gene synthesis and molecular cloning services.
• Offers oligonucleotide synthesis services.
• Specializes in protein engineering and peptide synthesis.
• Develops and produces antibody development services.
• Creates molecular diagnostics tools.
• Offers genome editing materials.
• Develops chimeric antigen receptor T-cell therapies.

How Does GNNSF Make Money?

• Provides fee-for-service research and development services to pharmaceutical and biotechnology companies.
• Sells life science research products, including reagents, kits, and instruments.
• Develops and commercializes cell therapies for the treatment of cancer.
• Generates revenue through licensing agreements and royalties.

What Industry Does GNNSF Operate In?

Genscript Biotech Corporation operates within the rapidly growing biotechnology industry, driven by increasing demand for advanced research tools, biologics development services, and cell therapies. The market is characterized by intense competition, rapid technological advancements, and stringent regulatory requirements. Genscript's diverse service offerings and global presence position it to capitalize on the increasing demand for outsourced research and development services from pharmaceutical and biotechnology companies. The company's focus on cell therapy also aligns with the growing interest in personalized medicine and innovative cancer treatments.

Who Are GNNSF's Key Customers?

• Pharmaceutical companies
• Biotechnology companies
• Government research institutions
• Academic research institutions
• Food and chemical industries

Company Profile

Genscript Biotech Corporation operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Hong Kong, HK. The company is led by CEO Weihui Shao. GNNSF has traded publicly since 2017.

Return on equity for Genscript Biotech Corporation stands at -16.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 2.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.5%, the inverse of the P/E and a quick read on earnings relative to price.

GNNSF Valuation & Market Position

With a $8.96B market cap, Genscript Biotech Corporation sits in the mid-cap segment of the market.

Quarterly Financial Performance: Genscript Biotech Corporation

Revenue for Genscript Biotech Corporation came in at $403.2M during Q2 FY2026, a 8.7% contraction versus the preceding quarter. The company recorded a net loss of $129.0M, with diluted EPS of $-0.06. Revenue has contracted over three consecutive quarters, which investors in this mid-cap Healthcare stock should monitor closely. Across the four most recent quarters, GNNSF averaged $0.28 in diluted EPS.

Genscript Biotech Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.80 places it in the safe zone, indicating low near-term bankruptcy risk.

Genscript Biotech Corporation has missed Wall Street's EPS estimate in 3 of its last 5 reported quarters — a mixed record worth weighing. Reported results have landed about 2683.1% above estimates on average.

GNNSF Financials

GNNSF Latest News

GNNSF Analyst Consensus

GNNSF MoonshotScore

Common Questions About GNNSF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources